Reference

New therapies for chronic hepatitis B infection

All Rights Reserved. New therapies for chronic hepatitis B infection. Chang, T. T. 142217-69-4 and 3424-98-4 are also occured in this study.; Jia, Jidong D.; Omata, Masao; Yoon, S. K. (College of Medicine, National Cheng Kung University, Tainan, Taiwan). Liver International, 26(Suppl. 2), 30-37 (English) 2006 Blackwell Publishing Ltd. CODEN: LIINCM. ISSN: 1478-3223. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Conventional pharmacotherapeutic approaches to the management of chronic hepatitis B virus (HBV) infection are compromised by drug resistance and a failure to achieve sustained HBV DNA suppression. Low rates of seroconversion to hepatitis B e antigen-neg. status and loss of hepatitis B surface antigen, as well as the potential for the development of adverse effects, are addnl. problems. Two agents, entecavir and the pegylated interferon (peginterferon) a-2a, have recently been added to the therapeutic armamentarium for the management of chronic hepatitis B (CHB). Data from clin. trials indicate that these newly licensed drugs may offer advantages over conventional treatments such as lamivudine and, possibly, adefovir. In addn., several novel agents in late-stage clin. development, specifically telbivudine and clevudine, have also shown encouraging results in patients with CHB infection. This review summarizes the current clin. experience with these new agents, focusing on data in Asian populations, and discusses the implications of the data for CHB management. .

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Lai, Ching-Lung; Lim, Seng Gee; Brown, Nathaniel A.; Zhou, Xiao-Jian; Lloyd, Deborah M.; Lee, Yin-Mei; Yuen, Man-Fung; Chao, George C.; Myers, Maureen W. (University of Hong Kong, Hong Kong, Peop. Rep. China). Hepatology (Hoboken, NJ, United States), 40(3), 719-726 (English) 2004 John Wiley & Sons, Inc. CODEN: HPTLD9. ISSN: 0270-9139. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability.Some commonly used reagents like 3424-98-4 is used in this experiment. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclin. safety profile. In this first clin. study of telbivudine, safety, antiviral activity, and pharmacokinetics were assessed in 43 adults with hepatitis B e antigen-pos. chronic hepatitis B. This placebo-controlled dose-escalation trial investigated 6 telbivudine daily dosing levels (25, 50, 100, 200, 400, and 800 mg/d); treatment was given for 4 wk, with 12 wk' follow-up. Serum HBV DNA levels were monitored via quant. polymerase chain reaction. The results indicate that telbivudine was well tolerated at all dosing levels, with no dose-related or treatment-related clin. or lab. adverse events. Telbivudine plasma pharmacokinetics were dose-proportional within the studied dose range. Marked dose-related antiviral activity was evident, with a max. at telbivudine doses of 400 mg/d or more. In the 800mg/d cohort, the mean HBV DNA redn. was 3.75 log10 copies/mL at week 4, comprising a 99.98% redn. in serum viral load. Correspondingly, posttreatment return of viral load was slowest in the high-dose groups. Viral dynamic analyses suggested a high degree of efficiency of inhibition of HBV replication by telbivudine and helped refine selection of the optimal dose. In conclusion, these results support expanded clin. studies of this new agent for the treatment of hepatitis B. .